Skip to content
Disclosery

Royalty Pharma Sub-Manager, LLC

Follow

13F filer, CIK 2081668, New York, NY

Royalty Pharma Sub-Manager, LLC reported $241,917,580 across 4 holdings for the quarter ended 2026-06-30, in a 13F-HR/A filed 2026-08-21.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0002081668-26-000018

Period
2026-06-30
Reported value
$242M
Holdings
4
Top 10 weight
100%
New
1
Sold out
1

Part of the filer group Royalty Pharma Sub-Manager, LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KLRAnew+2,455,357$54.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BCRXexited-3,846,154-$36.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR/A 0002081668-26-000018, largest first. % of portfolio is the value over $241,917,580, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 980,392 shares; 2026Q1: 980,392 shares; 2026Q2: 980,392 shares 980,392$83.5M34.52%0Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,263,150 shares; 2026Q1: 2,388,150 shares; 2026Q2: 2,388,150 shares 2,388,150$60.6M25.05%0Timeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,455,357 shares 2,455,357$54.1M22.36%newTimeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 2,936,507 shares; 2026Q1: 2,936,507 shares; 2026Q2: 2,936,507 shares 2,936,507$43.7M18.06%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BCRXBIOCRYST PHARMACEUTICALS INC3,846,154$36.6Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0002081668-26-000009 superseded2026-08-14acceptance time not in the bulk data set
13F-HR/A 0002081668-26-000018 baserestatement2026-08-21acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR/A 0002081668-26-000015 Quarter ended 2025-12-312026-08-21acceptance time not in the bulk data set
13F-HR/A 0002081668-26-000018 Quarter ended 2026-06-302026-08-21acceptance time not in the bulk data set
13F-HR/A 0002081668-26-000017 Quarter ended 2026-03-312026-08-21acceptance time not in the bulk data set
13F-HR 0002081668-26-000009 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0002081668-26-000006 Quarter ended 2026-03-312026-05-14acceptance time not in the bulk data set
13F-HR 0002081668-26-000003 Quarter ended 2025-12-312026-04-01acceptance time not in the bulk data set